PEGylated analogue of an IGF-1 splice-variant fragment called mechano growth factor
PRODUCT PROFILE
PEG-MGF
£61.00
PEG-MGF is pegylated analogue of an igf-1 splice-variant fragment called mechano growth factor. Researchers examine it in relation to muscle loading, satellite-cell and tissue-repair hypotheses.
Why it is distinct
A modified splice-variant fragment rather than a direct full IGF-1 receptor analogue.
- Evidence stageExperimental
- AvailabilityUnavailable
- Batch recordPublished after verification
- DispatchConfirmed at checkout
Out of stock
Ask about availabilityPRODUCT INFORMATION
Clear first. Detailed when needed.
What this material is+
PEG-MGF is pegylated analogue of an igf-1 splice-variant fragment called mechano growth factor. Researchers examine it in relation to muscle loading, satellite-cell and tissue-repair hypotheses.
Research focus+
Researchers study whether it can influence repair signals and muscle stem cells after mechanical stress. Claims about muscle growth are not supported by robust human trials.
How the mechanism differs+
PEGylation is intended to prolong exposure to an MGF-related peptide fragment; product sequence and chemistry vary between suppliers.
Evidence and limitations+
Predominantly preclinical with very limited validation of commercial PEG-MGF materials and no established human outcomes.
Testing and batch documentation+
No live certificate is shown for this staging item. ADINA will only publish a batch document after the product identifier, test method and result have been checked.
RESEARCH PROFILE
Understand the distinction.
Researchers study whether it can influence repair signals and muscle stem cells after mechanical stress. Claims about muscle growth are not supported by robust human trials.
PEGylation is intended to prolong exposure to an MGF-related peptide fragment; product sequence and chemistry vary between suppliers.
A modified splice-variant fragment rather than a direct full IGF-1 receptor analogue.
Predominantly preclinical with very limited validation of commercial PEG-MGF materials and no established human outcomes.
Educational research context only. This information is not dosage, administration or personal-use guidance.
CONTINUE EXPLORING
Related research perspectives.
Selected for useful comparison across neighbouring or contrasting research areas—not as combined-use guidance.
-
Experimental
Follistatin 344
£76.001 mgBatch file pendingA ligand-binding inhibitor of the activin/myostatin system, not a GH or IGF secretagogue.
UnavailableAsk about availability -
Early human evidence
CJC-1295 No DAC
Price range: £25.99 through £32.995 mgBatch file pendingShort-duration GHRH signalling, in contrast with albumin-bound, long-acting CJC-1295 DAC.
UnavailableAsk about availability This product has multiple variants. The options may be chosen on the product page -
Established
Sermorelin
£49.005 mgBatch file pendingClosest to the natural active GHRH sequence and shorter acting than tesamorelin or CJC-1295 DAC.
UnavailableAsk about availability -
Early human evidence
Hexarelin
£51.005 mgBatch file pendingA potent older GHRP with less hormonal selectivity than ipamorelin.
UnavailableAsk about availability